Equity Overview
Price & Market Data
Price: $0.019
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $3,629,589
Daily Volume: 0
Performance Metrics
1 Week: -18.80%
1 Month: -17.39%
3 Months: 533.3%
6 Months: 1,018%
1 Year: 111.1%
YTD: -72.02%
Details
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.